Select Language:
The Swiss pharmaceutical giant is planning to invest over CNY3.3 billion (USD460 million) in China, allocating approximately CNY1.5 billion to boost innovative drug production at its Beijing facility, with the remaining funds aimed at enhancing capabilities at its research and development center in Shanghai’s Zhangjiang Hi-Tech Park. The company announced this substantial new investment plan during the opening of the annual China Development Forum yesterday. The plan involves constructing new workshops and support infrastructure at the Beijing plant, incorporating advanced manufacturing technologies such as sterile preparation, liquid filling, and packaging equipment.
The Beijing factory is the company’s largest manufacturing site for branded prescription medications in China and plays a key role in its global pharmaceutical supply chain. Its primary focus is on producing oral solid dosage forms.
China is vital to the company’s long-term growth and innovation strategy. The CEO emphasized that the company remains committed to delivering innovative medicines to Chinese patients and aims to be the country’s most valued and trusted healthcare partner.
The Shanghai facility serves as the company’s third-largest research and development center and functions as a hub for its Asia-Pacific operations. In addition, the company operates a generic drug manufacturing plant in Guangdong province and is constructing China’s first radiopharmaceutical ligand therapy production facility in Zhejiang province.
China has emerged as a global leader in pharmaceutical innovation, prompting multinational companies to increase investments and collaborate with local pharmaceutical innovators. These efforts are designed to accelerate innovation and speed up the introduction of new drugs to the Chinese market.
Earlier this month, an American pharmaceutical company announced a USD3 billion investment over the next decade to develop a production and supply system for oral solid formulations in China, supporting the expansion of supply chain capacity for its next-generation weight-loss medication. In late January, a UK-Swedish rival announced plans to invest over USD15 billion in China through 2030 to expand drug manufacturing and R&D capabilities.
ChatGPT
Perplexity
Gemini AI
Grok AI
